Join TAG on April 16 at 8:30 a.m. ET for a practical webinar on drug safety monitoring in TB treatment. Learn how to identify side effects, support patient safety, and understand pharmacovigilance in the context of newer, all-oral DR-TB regimens.
New tuberculosis research presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver offers important updates on TB prevention and treatment for people living with HIV. TAG summarizes key findings on short-course preventive therapy, treatment dosing strategies, and emerging long-acting technologies. Read TAG’s analysis.
What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines, written together with community partners and supported by Wellcome, explores the indispensable role of communities and civil society in preparing the way for new TB vaccines and ensuring their success once they become available.
New tuberculosis (TB) vaccines could be realized as soon as 2028 — radically reshaping the journey to eliminate TB. Communities and civil society organizations are poised to play a vital role in the introduction of a future TB vaccine as central protagonists of this next chapter for TB elimination.
TAGLine 2025 documents a year of action as Treatment Action Group defended science, confronted attacks on public health, and fought to protect communities impacted by HIV, TB, and HCV.
From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first of its kind analysis of the global supply chains of two key adjuvants used in several of the world’s most important vaccines.
On Friday, RFK Jr’s vaccine denialist-dominated Advisory Committee on Immunization Practices (ACIP) voted to no longer recommend immediate post-partum / birth vaccination of babies with hepatitis B virus (HBV) vaccine.
Treatment Action Group (TAG) welcomes the report published today by the World Health Organization TB Vaccine Accelerator Council on how to finance global, equitable access to new TB vaccines.
On Friday May 30, it was reported that National Institutes of Health (NIH) leadership has unilaterally terminated funding for HIV vaccine research consortia that were making significant progress toward solving the stern challenge of inducing protective broadly neutralizing antibodies against the virus.
These are the remarks delivered by Mike Frick, TAG’s TB co-director, who was speaking as a civil society representative, at the 3rd meeting of the WHO Director-General’s TB Vaccine Accelerator Council on May 20, 2025 in Geneva, Switzerland.